Upregulation of miR-17-92 cluster is associated with progression and lymph node metastasis in oesophageal adenocarcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 08 2019
20 08 2019
Historique:
received:
08
04
2019
accepted:
08
08
2019
entrez:
22
8
2019
pubmed:
23
8
2019
medline:
24
10
2020
Statut:
epublish
Résumé
The occurrence of lymph node metastasis (LNM) and depth of tumour infiltration are significant prognostic factors in oesophageal adenocarcinoma (OAC), however no reliable prognostic biomarkers have been established so far. Aim of this study was to characterize microRNAs (miRs) of OAC patients, who primarily underwent oesophagectomy, in order to identify specific alterations during tumour progression and LNM. MicroRNA array-based quantification analysis of 754 miRs, including tumour specimens of 12 patients with pT2 OAC from three different centres (detection group), was performed. We identified miR-17, miR-19a/b, miR-20a, and miR-106a, showing the best predictive power for LNM. These miRs were validated by quantitative real time-PCR (qRT-PCR) in 43 patients with different tumour stages (pT1: n = 21; pT2: n = 12 and pT3: n = 10) (training group) (p < 0.05), demonstrating that increasing levels of identified miRs were associated with advanced depth of tumour infiltration. These findings were verified in another independent group of 46 pT2 OAC patients (validation group). Quantitative RT-PCR analysis of the miR-panel confirmed these results except for miR-19a (p < 0.05 each). Logistic regression analysis identified miR-17 and miR-20a (p = 0.025 and p = 0.022, respectively) to be independent variables for prediction of LNM. The mathematical prediction model was used in the validation group, and the estimated prognosis was compared to the actual postsurgical follow-up. This comprehensive data demonstrated the importance of miR-17-92 cluster and miR-106a for progression as well as LNM in OAC indicating that those might be feasible prognostic biomarkers.
Identifiants
pubmed: 31431687
doi: 10.1038/s41598-019-48624-0
pii: 10.1038/s41598-019-48624-0
pmc: PMC6702344
doi:
Substances chimiques
Biomarkers, Tumor
0
MIR17HG, human
0
MIRN106 microRNA, human
0
MIRN17 microRNA, human
0
MIRN19 microRNA, human
0
MIRN20a microRNA, human
0
MicroRNAs
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12113Références
Oncotarget. 2017 Jul 8;8(40):69125-69138
pubmed: 28978185
Br J Cancer. 2013 May 14;108(9):1822-9
pubmed: 23579215
Cancer Epidemiol. 2016 Apr;41:88-95
pubmed: 26851752
Oncol Lett. 2019 Jan;17(1):863-870
pubmed: 30655840
Histol Histopathol. 2015 Oct;30(10):1193-202
pubmed: 25869644
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Cancer Lett. 2014 Mar 28;344(2):147-56
pubmed: 24184826
Biomed Pharmacother. 2016 Aug;82:509-19
pubmed: 27470391
J Gastrointest Surg. 2015 Jul;19(7):1208-15
pubmed: 25943911
Gastroenterology. 2015 Aug;149(2):302-17.e1
pubmed: 25957861
Mutat Res. 2011 Jun 17;722(2):94-105
pubmed: 20472093
Int J Oncol. 2011 Apr;38(4):1013-22
pubmed: 21271217
Cell Death Differ. 2013 Dec;20(12):1603-14
pubmed: 24212931
Lancet. 2017 Nov 25;390(10110):2383-2396
pubmed: 28648400
Int J Mol Sci. 2013 Jun 07;14(6):12273-96
pubmed: 23749113
Tumour Biol. 2015 Jun;36(6):4643-53
pubmed: 25631748
Cancer Prev Res (Phila). 2013 Mar;6(3):196-205
pubmed: 23466817
Oncotarget. 2017 Feb 14;8(7):11400-11413
pubmed: 28002789
J Gastrointest Oncol. 2018 Oct;9(5):887-893
pubmed: 30505591
Front Med (Lausanne). 2015 Sep 08;2:64
pubmed: 26442266
Nature. 2005 Jun 9;435(7043):828-33
pubmed: 15944707
Gastrointest Endosc. 2017 Aug;86(2):292-298
pubmed: 27889544
Cancer Epidemiol. 2017 Apr;47:114-117
pubmed: 28258029
J Thorac Cardiovasc Surg. 2019 Mar;157(3):1264-1272.e6
pubmed: 30558879
Biomark Med. 2017 May;11(5):431-441
pubmed: 28621611
Trends Mol Med. 2014 Aug;20(8):460-9
pubmed: 25027972
Dig Liver Dis. 2018 May;50(5):438-445
pubmed: 29573963
Ann Thorac Surg. 2014 Mar;97(3):1037-45
pubmed: 24360091
Ann Surg. 2011 Nov;254(5):731-6; discussion 736-7
pubmed: 21997815
Histol Histopathol. 2011 Oct;26(10):1353-61
pubmed: 21870338
Clin Radiol. 2017 Aug;72(8):693.e1-693.e7
pubmed: 28363659
Am J Gastroenterol. 2017 Aug;112(8):1247-1255
pubmed: 28585555
Ann Surg. 2011 Nov;254(5):802-7; discussion 807-8
pubmed: 22042472
Br J Radiol. 2016 Dec;89(1068):20160087
pubmed: 27767330
Cancer J. 2012 May-Jun;18(3):262-7
pubmed: 22647363
Expert Opin Biol Ther. 2014 Apr;14(4):483-9
pubmed: 24506707
FEBS Lett. 2014 Feb 14;588(4):600-7
pubmed: 24440352
Cancer Metastasis Rev. 2018 Mar;37(1):5-15
pubmed: 29234933
Ann Thorac Surg. 2015 Jun;99(6):1879-85; discussion 1886
pubmed: 25929888
Eur J Cancer Prev. 2017 Mar;26(2):107-118
pubmed: 27014938
Ann Surg. 2014 Jan;259(1):96-101
pubmed: 24096772
Endoscopy. 2006 Feb;38(2):149-56
pubmed: 16479422
Am J Cancer Res. 2016 Jul 01;6(7):1549-62
pubmed: 27508097
Cell Rep. 2016 Aug 16;16(7):1915-28
pubmed: 27498867
Int J Biochem Cell Biol. 2010 Aug;42(8):1348-54
pubmed: 20227518
Anticancer Res. 2017 Feb;37(2):403-412
pubmed: 28179285
World J Gastroenterol. 2015 Apr 21;21(15):4660-5
pubmed: 25914476
World J Gastroenterol. 2014 Oct 28;20(40):14904-12
pubmed: 25356050